Healthcare Industry News: Terumo
News Release - January 27, 2016
MetaCure Announces Appointment of New CEOHAMILTON, Bermuda, January 27, 2016 -- (Healthcare Sales & Marketing Network) -- MetaCure has announced the appointment of Adrian Gilmore as CEO. Gilmore brings over 20 years' experience in the healthcare and medical device industry, and will also join the company's board. Dr. Mateusz Zelewski becomes President of MetaCure, in addition to taking up the position of COO.
"This is an excellent time for Adrian to become MetaCure's CEO," said MetaCure's founder and Chairman, Professor Shlomo Ben-Haim. "During 2015 the results of three important trials studying the DIAMOND therapy were published and presented to the medical diabetes community - a long-term efficacy trial, a double-blinded cross-over trial and a pilot trial comparing DIAMOND with the gold standard insulin treatment. MetaCure also made substantial advancements in its technology, including the development of the smaller DIAMOND II system. With these promising achievements, MetaCure decided to expand its clinical and commercial operations worldwide. Adrian's unique ability to turn strategy and vision into exceptional execution and his proven leadership skills are exactly what MetaCure needs as it enters its next chapter of growth."
Adrian Gilmore is a proven business leader who has worked for globally renowned organizations including BD, Bayer, Terumo and CSP Technologies. Based primarily in sales, marketing and business development roles during the early part of his career, he later moved into general management and organizational leadership positions. He has been successful in both early stage and well-established businesses, including several companies closely associated with the diabetes segment.
"With over half a billion patients suffering from type 2 diabetes worldwide, the DIAMOND therapy has the rare potential to improve many millions of lives," Gilmore explained. "Executing the company's vision and delivering our commitment to patients, physicians, payers and employees is an incredibly exciting task and I cannot be more honored to assume it."
MetaCure is part of the pioneering Hobart Group of companies, founded by Professor Shlomo Ben-Haim. In an interview published in this month's edition of the CEO Magazine (link), Professor Ben-Haim shared his vision for the group and its companies: "In the constantly evolving field of healthcare, new technologies and scientific discoveries are required to reach medical breakthroughs. Hobart is committed to leverage new technologies to improve the lives of patients worldwide."
About type 2 diabetes
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 500 million people worldwide are affected by diabetes, with management costs exceeding $600 billion annually.
About DIAMOND therapy
DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin. The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections. Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss. DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA. For more information, visit http://www.MetaCure.com/DIAMOND.
MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device. For more information, visit http://www.MetaCure.com.
About Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit http://www.Hobart-Group.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.